APO Research
Talk to an analyst

APO RESEARCH · REPORT

Secondary Progressive Multiple Sclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Secondary Progressive Multiple Sclerosis Drug Industry Growth and Trends Forecast to 2032

19 December 2025114 pages

Choose your research edition.

Industry ResearchSecondary Progressive Multiple Sclerosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Secondary Progressive Multiple Sclerosis Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Secondary Progressive Multiple Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Secondary Progressive Multiple Sclerosis Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Secondary Progressive Multiple Sclerosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Secondary Progressive Multiple Sclerosis Drug include AB Science SA, Actelion Ltd, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Ltd, Kyorin Pharmaceutical Co., Ltd. and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Secondary Progressive Multiple Sclerosis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Secondary Progressive Multiple Sclerosis Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Secondary Progressive Multiple Sclerosis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Secondary Progressive Multiple Sclerosis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Secondary Progressive Multiple Sclerosis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Secondary Progressive Multiple Sclerosis Drug Market by Company

AB Science SA

Actelion Ltd

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.

Mallinckrodt Plc

MedDay SA

MedImmune, LLC

Merck KGaA

Meta-IQ ApS

Opexa Therapeutics, Inc.

Xenetic Biosciences (UK) Limited

Biogen, Inc.

Novartis AG

Secondary Progressive Multiple Sclerosis Drug Segment by Type

Etomoxir

Inebilizumab

IB-MS

GLX-1112

DC-TAB

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Application

Hospital

Clinic

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Progressive Multiple Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Secondary Progressive Multiple Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Progressive Multiple Sclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Secondary Progressive Multiple Sclerosis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Secondary Progressive Multiple Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Etomoxir Table 2. Major Company of Inebilizumab Table 3. Major Company of IB-MS Table 4. Major Company of GLX-1112 Table 5. Major Company of DC-TAB Table 6. Major Company of Others Table 7. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 14. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 19. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 21. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 25. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Secondary Progressive Multiple Sclerosis Drug Industry Trends Table 29. Secondary Progressive Multiple Sclerosis Drug Industry Drivers Table 30. Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges Table 31. Secondary Progressive Multiple Sclerosis Drug Industry Restraints Table 32. Global Secondary Progressive Multiple Sclerosis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2021-2026) Table 34. Global Secondary Progressive Multiple Sclerosis Drug Sales by Company (2021-2026) & (K Units) Table 35. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Company (2021-2026) Table 36. Global Secondary Progressive Multiple Sclerosis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Secondary Progressive Multiple Sclerosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Secondary Progressive Multiple Sclerosis Drug Major Company Production Sites and Headquarters Table 39. Global Secondary Progressive Multiple Sclerosis Drug Company, Product Type & Application Table 40. Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Secondary Progressive Multiple Sclerosis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 61. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 66. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 68. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 72. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (US$ Million) Table 75. AB Science SA Company Information Table 76. AB Science SA Business Overview Table 77. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 79. AB Science SA Recent Development Table 80. Actelion Ltd Company Information Table 81. Actelion Ltd Business Overview Table 82. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 84. Actelion Ltd Recent Development Table 85. F. Hoffmann-La Roche Ltd. Company Information Table 86. F. Hoffmann-La Roche Ltd. Business Overview Table 87. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 89. F. Hoffmann-La Roche Ltd. Recent Development Table 90. Genzyme Corporation Company Information Table 91. Genzyme Corporation Business Overview Table 92. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 94. Genzyme Corporation Recent Development Table 95. Glialogix, Inc. Company Information Table 96. Glialogix, Inc. Business Overview Table 97. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 99. Glialogix, Inc. Recent Development Table 100. Immune Response BioPharma, Inc. Company Information Table 101. Immune Response BioPharma, Inc. Business Overview Table 102. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 104. Immune Response BioPharma, Inc. Recent Development Table 105. Innate Immunotherapeutics Ltd Company Information Table 106. Innate Immunotherapeutics Ltd Business Overview Table 107. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 109. Innate Immunotherapeutics Ltd Recent Development Table 110. Kyorin Pharmaceutical Co., Ltd. Company Information Table 111. Kyorin Pharmaceutical Co., Ltd. Business Overview Table 112. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 114. Kyorin Pharmaceutical Co., Ltd. Recent Development Table 115. Mallinckrodt Plc Company Information Table 116. Mallinckrodt Plc Business Overview Table 117. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 119. Mallinckrodt Plc Recent Development Table 120. MedDay SA Company Information Table 121. MedDay SA Business Overview Table 122. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 124. MedDay SA Recent Development Table 125. MedImmune, LLC Company Information Table 126. MedImmune, LLC Business Overview Table 127. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 129. MedImmune, LLC Recent Development Table 130. Merck KGaA Company Information Table 131. Merck KGaA Business Overview Table 132. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 134. Merck KGaA Recent Development Table 135. Meta-IQ ApS Company Information Table 136. Meta-IQ ApS Business Overview Table 137. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 139. Meta-IQ ApS Recent Development Table 140. Opexa Therapeutics, Inc. Company Information Table 141. Opexa Therapeutics, Inc. Business Overview Table 142. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 144. Opexa Therapeutics, Inc. Recent Development Table 145. Xenetic Biosciences (UK) Limited Company Information Table 146. Xenetic Biosciences (UK) Limited Business Overview Table 147. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 149. Xenetic Biosciences (UK) Limited Recent Development Table 150. Biogen, Inc. Company Information Table 151. Biogen, Inc. Business Overview Table 152. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 154. Biogen, Inc. Recent Development Table 155. Novartis AG Company Information Table 156. Novartis AG Business Overview Table 157. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 159. Novartis AG Recent Development Table 160. North America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 161. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 162. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 163. North America Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 164. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 165. North America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 167. North America Secondary Progressive Multiple Sclerosis Drug Market Share by Country (2021-2026) Table 168. North America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. North America Secondary Progressive Multiple Sclerosis Drug Market Share Forecast by Country (2027-2032) Table 170. Europe Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 171. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 172. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 173. Europe Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 174. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 175. Europe Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 177. Europe Secondary Progressive Multiple Sclerosis Drug Market Share by Country (2021-2026) Table 178. Europe Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Europe Secondary Progressive Multiple Sclerosis Drug Market Share Forecast by Country (2027-2032) Table 180. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 181. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 182. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 183. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 184. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 185. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 187. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Share by Country (2021-2026) Table 188. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Share Forecast by Country (2027-2032) Table 190. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 191. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 192. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 193. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 194. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 195. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 197. Latin America Secondary Progressive Multiple Sclerosis Drug Market Share by Country (2021-2026) Table 198. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Latin America Secondary Progressive Multiple Sclerosis Drug Market Share Forecast by Country (2027-2032) Table 200. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 202. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 203. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 204. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Country (2027-2032) Table 205. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 207. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Share by Country (2021-2026) Table 208. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Share Forecast by Country (2027-2032) Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. Secondary Progressive Multiple Sclerosis Drug Distributors List Table 213. Secondary Progressive Multiple Sclerosis Drug Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. Secondary Progressive Multiple Sclerosis Drug Image Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Secondary Progressive Multiple Sclerosis Drug Sales (2021-2032) & (K Units) Figure 5. Etomoxir Image Figure 6. Global Etomoxir Sales YoY Growth (2021-2032) & (K Units) Figure 7. Inebilizumab Image Figure 8. Global Inebilizumab Sales YoY Growth (2021-2032) & (K Units) Figure 9. IB-MS Image Figure 10. Global IB-MS Sales YoY Growth (2021-2032) & (K Units) Figure 11. GLX-1112 Image Figure 12. Global GLX-1112 Sales YoY Growth (2021-2032) & (K Units) Figure 13. DC-TAB Image Figure 14. Global DC-TAB Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Type 2025 VS 2032 Figure 19. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Secondary Progressive Multiple Sclerosis Drug Market Share by Application 2025 VS 2032 Figure 39. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Secondary Progressive Multiple Sclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Secondary Progressive Multiple Sclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Secondary Progressive Multiple Sclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Secondary Progressive Multiple Sclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Secondary Progressive Multiple Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Secondary Progressive Multiple Sclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Secondary Progressive Multiple Sclerosis Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Secondary Progressive Multiple Sclerosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Etomoxir
  • Inebilizumab
  • IB-MS
  • GLX-1112
  • DC-TAB
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • AB Science SA
  • Actelion Ltd
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited
  • Biogen, Inc.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Secondary Progressive Multiple Sclerosis Drug Market by Type
  6. 1.3.1 Etomoxir
  7. 1.3.2 Inebilizumab
  8. 1.3.3 IB-MS
  9. 1.3.4 GLX-1112
  10. 1.3.5 DC-TAB
  11. 1.3.6 Others
  12. 1.4 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  13. 1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
  2. 2.2 Secondary Progressive Multiple Sclerosis Drug Industry Drivers
  3. 2.3 Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Secondary Progressive Multiple Sclerosis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Price (2021-2026)
  4. 3.4 Global Secondary Progressive Multiple Sclerosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Secondary Progressive Multiple Sclerosis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Secondary Progressive Multiple Sclerosis Drug Company, Product Type & Application
  7. 3.7 Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Secondary Progressive Multiple Sclerosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Secondary Progressive Multiple Sclerosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Secondary Progressive Multiple Sclerosis Drug Tier 1, Tier 2, and Tier 3
4 Secondary Progressive Multiple Sclerosis Drug Regional Status and Outlook
  1. 4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Region
  3. 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Secondary Progressive Multiple Sclerosis Drug by Application
  1. 5.1 Secondary Progressive Multiple Sclerosis Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AB Science SA
  2. 6.1.1 AB Science SA Company Information
  3. 6.1.2 AB Science SA Business Overview
  4. 6.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  6. 6.1.5 AB Science SA Recent Developments
  7. 6.2 Actelion Ltd
  8. 6.2.1 Actelion Ltd Company Information
  9. 6.2.2 Actelion Ltd Business Overview
  10. 6.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  12. 6.2.5 Actelion Ltd Recent Developments
  13. 6.3 F. Hoffmann-La Roche Ltd.
  14. 6.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 6.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 6.3.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  18. 6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 6.4 Genzyme Corporation
  20. 6.4.1 Genzyme Corporation Company Information
  21. 6.4.2 Genzyme Corporation Business Overview
  22. 6.4.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  24. 6.4.5 Genzyme Corporation Recent Developments
  25. 6.5 Glialogix, Inc.
  26. 6.5.1 Glialogix, Inc. Company Information
  27. 6.5.2 Glialogix, Inc. Business Overview
  28. 6.5.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  30. 6.5.5 Glialogix, Inc. Recent Developments
  31. 6.6 Immune Response BioPharma, Inc.
  32. 6.6.1 Immune Response BioPharma, Inc. Company Information
  33. 6.6.2 Immune Response BioPharma, Inc. Business Overview
  34. 6.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  36. 6.6.5 Immune Response BioPharma, Inc. Recent Developments
  37. 6.7 Innate Immunotherapeutics Ltd
  38. 6.7.1 Innate Immunotherapeutics Ltd Company Information
  39. 6.7.2 Innate Immunotherapeutics Ltd Business Overview
  40. 6.7.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  42. 6.7.5 Innate Immunotherapeutics Ltd Recent Developments
  43. 6.8 Kyorin Pharmaceutical Co., Ltd.
  44. 6.8.1 Kyorin Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  48. 6.8.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Mallinckrodt Plc
  50. 6.9.1 Mallinckrodt Plc Company Information
  51. 6.9.2 Mallinckrodt Plc Business Overview
  52. 6.9.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  54. 6.9.5 Mallinckrodt Plc Recent Developments
  55. 6.10 MedDay SA
  56. 6.10.1 MedDay SA Company Information
  57. 6.10.2 MedDay SA Business Overview
  58. 6.10.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  60. 6.10.5 MedDay SA Recent Developments
  61. 6.11 MedImmune, LLC
  62. 6.11.1 MedImmune, LLC Company Information
  63. 6.11.2 MedImmune, LLC Business Overview
  64. 6.11.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  66. 6.11.5 MedImmune, LLC Recent Developments
  67. 6.12 Merck KGaA
  68. 6.12.1 Merck KGaA Company Information
  69. 6.12.2 Merck KGaA Business Overview
  70. 6.12.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  72. 6.12.5 Merck KGaA Recent Developments
  73. 6.13 Meta-IQ ApS
  74. 6.13.1 Meta-IQ ApS Company Information
  75. 6.13.2 Meta-IQ ApS Business Overview
  76. 6.13.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  78. 6.13.5 Meta-IQ ApS Recent Developments
  79. 6.14 Opexa Therapeutics, Inc.
  80. 6.14.1 Opexa Therapeutics, Inc. Company Information
  81. 6.14.2 Opexa Therapeutics, Inc. Business Overview
  82. 6.14.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  84. 6.14.5 Opexa Therapeutics, Inc. Recent Developments
  85. 6.15 Xenetic Biosciences (UK) Limited
  86. 6.15.1 Xenetic Biosciences (UK) Limited Company Information
  87. 6.15.2 Xenetic Biosciences (UK) Limited Business Overview
  88. 6.15.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  90. 6.15.5 Xenetic Biosciences (UK) Limited Recent Developments
  91. 6.16 Biogen, Inc.
  92. 6.16.1 Biogen, Inc. Company Information
  93. 6.16.2 Biogen, Inc. Business Overview
  94. 6.16.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  96. 6.16.5 Biogen, Inc. Recent Developments
  97. 6.17 Novartis AG
  98. 6.17.1 Novartis AG Company Information
  99. 6.17.2 Novartis AG Business Overview
  100. 6.17.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  102. 6.17.5 Novartis AG Recent Developments
7 North America by Country
  1. 7.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country
  2. 7.1.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  6. 7.2.1 North America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country
  2. 8.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  6. 8.2.1 Europe Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Secondary Progressive Multiple Sclerosis Drug Sales by Country
  2. 10.1.1 South America Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  6. 10.2.1 South America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Secondary Progressive Multiple Sclerosis Drug Value Chain Analysis
  2. 12.1.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Secondary Progressive Multiple Sclerosis Drug Production Mode & Process
  7. 12.2 Secondary Progressive Multiple Sclerosis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Secondary Progressive Multiple Sclerosis Drug Distributors
  10. 12.2.3 Secondary Progressive Multiple Sclerosis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst